News Breaks |
|
|
| January 30, 2013 |
| 05:36 EDT |  | PSTI | Pluristem takes possession of, moves into new manufacturing facility
Pluristem Therapeutics announced that the company has taken possession of and is moving into its new state-of-the-art GMP facility. The facility allows for the production of mass quantities of PLacental eXpanded cells that possess the advantages of being grown utilizing Pluristem's patented 3D bioreactor technology. The new manufacturing facility will have the capability to produce different PLX product candidates with the potential capacity of over 150,000 doses annually. Additionally, if more indications are approved by regulators for clinical trials, this new facility will enable us to supply PLX cells to conduct these additional trials in parallel. |
|
|
News For PSTI From The Last 14 Days Check below for free stories on PSTI the last two weeks. |
|
|
| June 12, 2013 |
| 09:40 EDT |  | PSTI | Pluristem Therapeutics management to meet with Oppenheimer
Meeting to be held in New York on June 13 hosted by Oppenheimer. |
|
| June 10, 2013 |
| 07:20 EDT | | PSTI | Biomed to host a conference
 Subscribe for More Information |
|
| June 6, 2013 |
| 10:36 EDT | | PSTI | Pluristem Therapeutics management to meet with Oppenheimer
Subscribe for More Information |
|
| 10:34 EDT | | PSTI | Pluristem CEO says FDA hold has no effect on other trials outside U.S.
Subscribe for More Information |
|
| June 4, 2013 |
| 13:06 EDT |  | PSTI | Pluristem Therapeutics downgraded to Hold from Buy at Maxim
Subscribe for More Information |
|
| 09:07 EDT | | PSTI | Pluristem Therapeutics to receive clinical-hold notice from FDA
Subscribe for More Information |
|
| 08:57 EDT | | PSTI | Pluristem Therapeutics trading halted, pending news
|
|
|
|
|
|
